Overview of experimental strategy and derivation of iPSC-derived macrophages (iM0) from healthy and CF donors. (IMAGE)
Caption
Figure 1. Overview of experimental strategy and derivation of iPSC-derived macrophages (iM0) from healthy and CF donors. (A) Schematic representation of experimental goals; (B) Table of iPSC lines from healthy and CF donors used in the study; (C) CD11b+ flow cytometry profiles of healthy and CF iPSC-derived CD14+ iM0 (red is each donor; blue is the negative control); (D) Immunofluorescent staining of healthy and CF iM0 for CD68 (magenta), phalloidin (green) and nuclei (DAPI), attached on FBS-coated glass cover slips; (E) Example Giemsa-Wright staining showing morphology of cytospun CF iM0; (F) Phagocytic functions of healthy and CF iM0 using phagocytosis of Latex+ microbeads. Created in BioRender.com. CF: cystic fibrosis; DAPI: 4′,6-diamidino-2-phenylindole.
Credit
© 2026 Gordana Vunjak-Novakovic, et al. This is an Open Access article licensed under a Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, sharing, adaptation, distribution and reproduction in any medium or format, for any purpose, even commercially, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
Usage Restrictions
Credit must be given to the creator.
License
CC BY